Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03828617 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,710
- Enrollment target
NCT03828617 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,710 participants.
The verdict
NCT03828617, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,710 participants
- Enrollment target
Study Summary
This is a Phase 3, randomized, double-blind study with a 4-arm parallel design. Adults 18 through 49 years of age with no history of pneumococcal vaccination will be randomized in a 2:2:2:1 ratio to receive a single dose of: 20vPnC Lot 1; 20vPnC Lot 2; 20vPnC Lot 3; or 13vPnC.
Interventions
- BIOLOGICAL 13vPnC
- BIOLOGICAL 20vPnC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,710 participants |
| Start Date | 2019-02-14 |
| Est. Completion | 2019-10-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03828617
The ClinicalTrials.gov registry entry for NCT03828617 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,710 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 13vPnC is the first listed.
NCT03828617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03828617 about?
NCT03828617 is a clinical study titled "Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults". This is a Phase 3, randomized, double-blind study with a 4-arm parallel design. Adults 18 through 49 years of age with no history of pneumococcal vaccination will be randomized in a 2:2:2:1 ratio to receive a single dose of: 20vPnC Lot 1; 20vPnC Lot 2; 20vPnC Lot 3; or 13vPnC.
What is the current status of trial NCT03828617?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,710 participants. The study started on 2019-02-14. Estimated completion is 2019-10-09.
What interventions are being tested in trial NCT03828617?
The interventions under investigation include: 13vPnC (BIOLOGICAL), 20vPnC (BIOLOGICAL).
Who is sponsoring clinical trial NCT03828617?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.